Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32750
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLe, Khang Duy Ricky-
dc.contributor.authorChoy, Kay-Tai-
dc.contributor.authorRoth, Sara-
dc.contributor.authorHeriot, Alexander G-
dc.contributor.authorKong, Joseph C H-
dc.date2023-
dc.date.accessioned2023-04-26T05:24:20Z-
dc.date.available2023-04-26T05:24:20Z-
dc.date.issued2023-06-
dc.identifier.citationANZ Journal of Surgery 2023; 93(6)en_US
dc.identifier.issn1445-2197-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32750-
dc.description.abstractThis study aims to review and summarize the current up to date literature that explore the current treatment approaches to immune mediated colitis and the role of surgical specialties in the landscape of management. A narrative review of papers was performed following a literature search through Medline, EMBASE and Cochrane Central databases pertaining to immune mediated colitis as an adverse event of cancer immunotherapy. Current guidelines for the diagnosis and treatment of immune mediated colitis mirror the approach to the workup of inflammatory bowel disease and guided by treating oncology and gastroenterology specialties. Immune mediated colitis however relies on surgical specific skills as a consequence of obtaining a diagnosis as well as in the management of complications that may arise. Immune mediate colitis management has largely been under the purview of medical specialties. This review explores the current landscape of managing immune mediated colitis from a surgical perspective and highlights key areas in which surgeons can engage in the multidisciplinary care of this condition. To facilitate prompt diagnosis and management of immune-mediated colitis, there is an increasing necessity for surgeons to become familiar with the latest multidisciplinary approaches and recommendations.en_US
dc.language.isoeng-
dc.subjectcheckpoint inhibitor induced colitisen_US
dc.subjectcheckpoint inhibitorsen_US
dc.subjectcolonen_US
dc.subjectcytotoxic T-lymphocyte associated antigen 4en_US
dc.subjectimmune checkpoint inhibitorsen_US
dc.subjectimmune mediated colitisen_US
dc.subjectimmune related adverse eventsen_US
dc.subjectimmune therapyen_US
dc.subjectimmunotherapyen_US
dc.subjectimmunotherapy induced colitisen_US
dc.subjectprogrammed cell death protein 1en_US
dc.subjectprogrammed death ligand 1en_US
dc.titleImmune mediated colitis: a surgical perspective.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleANZ Journal of Surgeryen_US
dc.identifier.affiliationDepartment of General Surgical Specialties, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSurgeryen_US
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationGeelong Clinical School, Deakin University, Geelong, Victoria, Australia.en_US
dc.identifier.doi10.1111/ans.18485en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-4532-8248en_US
dc.identifier.orcid0000-0001-5763-5742en_US
dc.identifier.orcid0000-0001-9846-8776en_US
dc.identifier.orcid0000-0002-1392-2480en_US
dc.identifier.pubmedid37088921-
local.name.researcherChoy, Kay T
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
crisitem.author.deptSurgery-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Dec 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.